Literature DB >> 7797835

Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt.

T M Sturgis1.   

Abstract

Hepatorenal syndrome (HRS), a functional renal failure associated with severe liver disease, is believed to result from diminished effective arterial volume and altered renal hemodynamics. Death is almost inevitable after its development and therapeutic options are limited. Surgical shunts carry an increase in morbidity and mortality, and peritoneovenous shunts are frequently complicated by infection and coagulopathy. We report a case of hepatorenal syndrome successfully treated with transjugular intrahepatic portosystemic shunt (TIPS). This is an unusual therapeutic option for HRS and may lead to future indications for TIPS.

Entities:  

Mesh:

Year:  1995        PMID: 7797835

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Hepatorenal syndrome.

Authors:  Bimaljit Singh Sandhu; Arun J Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2005-12

2.  Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Authors:  K A Brensing; J Textor; J Perz; P Schiedermaier; P Raab; H Strunk; H U Klehr; H J Kramer; U Spengler; H Schild; T Sauerbruch
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

3.  Renal haemodynamics and function following partial portal decompression.

Authors:  Sharona Ross; Donald Thometz; Francesco Serafini; Mark Bloomston; Connor Morton; Emmanuel Zervos; Alexander Rosemurgy
Journal:  HPB (Oxford)       Date:  2009-05       Impact factor: 3.647

Review 4.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.